Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

You may also be interested in...



MorphoSys Takes MOR202 Back From Celgene, Will Seek New Partner

MorphoSys is putting on a brave face after Celgene handed back rights to its anti-CD38 monoclonal antibody MOR202, saying it will carry on with current trials in multiple myeloma patients and voicing confidence it can find another commercial partner “once the time is right.”

MorphoSys: Accelerating The Long Transformation

Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.

MorphoSys Fills Out Pipeline With Xencor Deal

After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel